Are you looking for expert advice...

Boots Digital Health is launching SureLeaf, a private medical cannabis service, bringing the treatment into the spotlight through a name familiar to millions of patients. The announcement marks a significant development in the UK’s medical cannabis sector.

The Society is pleased to have welcomed new members from Boots to the Society over the last few months.

What does the Boots medical cannabis announcement mean for healthcare professionals?

We expect the launch of SureLeaf to prompt more conversations between patients, GPs, pharmacists and other healthcare professionals. Colleagues may find themselves answering questions about medical cannabis, whether or not they are involved in prescribing.

Having access to clear information, practical guidance and colleagues with relevant experience can help healthcare professionals approach those conversations with confidence. Understanding the evidence, potential risks and uncertainties matters alongside knowing how assessment, prescribing and ongoing care work.

MCCS will continue to support clinicians with education, evidence resources and an independent professional community as patient interest grows.

Congratulations to the Boots team, and a warm welcome to our newest members.

Want to know more about medical cannabis?

Whether you are considering prescribing, already working in this area or supporting patients who receive cannabis-based medicines, MCCS offers practical guidance, education and peer support.

You do not need to be an existing prescriber to join. Our community welcomes doctors, pharmacists, nurses and other healthcare professionals who want to develop their understanding.

Join the Medical Cannabis Clinicians Society to access resources, learning opportunities and support from experienced colleagues.

The Medical Cannabis Clinicians Society is delighted to congratulate two of our members, Consultant Dr Dave Howells and Pharmacist Umesh Chauhan, on their wins at the Cannabis Industry Awards 2026.

Held on Wednesday 11 November at the Honourable Artillery Company in London, the annual awards, organised by the Cannabis Industry Council (CIC), celebrated the individuals making an outstanding contribution to the UK’s cannabis sector.

We were particularly pleased to see two Society members recognised for their dedication to patient care, professional standards and the continued development of cannabis-based medicine in the UK.

Dr Dave Howells – Hannah Deacon Doctor of the Year

A huge congratulations to Dr Dave Howells, Consultant Psychiatrist and Co-Founder of Cannabis Clinic Cardiff, who received the Hannah Deacon Doctor of the Year Award, presented by British Cannabis.

Named for Hannah, our late co-founder and former Executive Director, this award holds a particularly special meaning for everyone at the Society. Hannah’s determination helped change UK law in 2018 and transform access to medical cannabis for patients. Following her death in May 2025, her courage, compassion and unwavering commitment to patients continue to inspire our work. It is lovely to see Dr Howells recognised with an award celebrating the qualities Hannah championed throughout her life: leadership, compassion and a determination to improve patient care.

Dr Howells qualified as a doctor in Cardiff in 2001 and has worked in mental health for more than 20 years, specialising in Old Age Psychiatry since 2007. In 2021, he co-founded Cannabis Clinic Cardiff to help address the unmet needs of patients with mental health conditions who may benefit from prescribed medical cannabis.

A compassionate and patient-focused clinician, Dr Howells is committed to improving access to standardised, quality-assured cannabis-based medicinal products. His recognition is a great achievement and reflects the importance of experienced clinicians working to improve treatment options for patients.

Umesh Chauhan – Pharmacist of the Year

Congratulations also to Umesh Chauhan, Founder and Superintendent Pharmacist of Specials Pharma, who was named Pharmacist of the Year, presented by Curaleaf Laboratories.

The award recognises pharmacists demonstrating outstanding commitment to patient care, professional excellence and leadership in medical cannabis pharmacy practice.

Umesh founded Specials Pharma following the change in UK medical cannabis legislation in 2018, helping to establish one of the country’s leading independent pharmacies specialising in cannabis-based medicinal products. With extensive experience in pharmaceutical regulation and medicines distribution, Umesh has played an important role in navigating the complexities of the UK’s medical cannabis supply chain.

He is particularly passionate about improving understanding of cannabis-based medicines within the pharmacy profession, supporting safe dispensing practices and helping patients access prescribed treatments.

His award is a fantastic recognition of the vital role pharmacists play in ensuring the safe, effective and reliable supply and prescribing of cannabis-based medicines.

Celebrating Excellence Across the Sector

We would also like to extend our congratulations to our members shortlisted for this year’s awards.

A special mention goes to fellow Doctor of the Year nominee Dr Simon Tordoff, Lead Clinician and Consultant in Pain Management at CB1 Medical and Pharmacist of the Year nominee Stefen David, Senior Pharmacy Manager at Curaleaf Pharmacy.

For the Society, it is particularly encouraging to see the contributions of doctors and pharmacists recognised alongside those working in research, advocacy and the wider industry. These healthcare professionals are central to building confidence in cannabis-based medicines, improving clinical practice and ensuring that patient care remains at the heart of the sector’s development.

Congratulations once again to Dave and Umesh on their well-deserved awards, and to everyone nominated. We are proud to have you as part of the Medical Cannabis Clinicians Society community and delighted to see your contributions recognised.

Each month, we bring together the key news stories shaping the medical cannabis landscape in the UK and beyond.

This month’s headlines highlight the evolving place of cannabis-based medicines in healthcare, research and public policy.

🇬🇧 UK epilepsy patients 

Five UK epilepsy charities have called on the government to intervene to secure the future supply of the high-CBD oil, Bedrolite, for seven patients, including children and young people with severe treatment-resistant epilepsy. The MCCS, along with patient advocacy groups, has also written to the Secretary of State for Health and Social Care, after Dutch producer Bedrocan went insolvent. Some families have now received confirmation from the Glasgow-based drug manufacturer Target that a six-month supply of the oil is available for existing patients, and it is continuing to work “towards a plan”, but the future of the supply remains uncertain. 

🇬🇧 Patient Safety Commissioner calls for medical cannabis safeguards 

The Independent highlighted concerns about private prescribing of unlicensed CBPMs, following the publication of new figures showing nearly two million items were prescribed privately in England between June 2025 and May 2026. Patient Safety Commissioner Professor Henrietta Hughes called for immediate measures to safeguard patients obtaining medical cannabis through online platforms.

Professor Mike Barnes, chair of the MCCS, was quoted in the article highlighting our good practice guide which aims “to provide a clear framework for safe, responsible prescribing, including thorough patient assessment, peer review, careful documentation, appropriate follow-up and clinician training – principles that align closely with the expectations set out by the Care Quality Commission”.

🇬🇧 Jersey to introduce tighter rules for medical cannabis prescribing 

Following growing concern about the impact of the increased prevalence of CBPMs on mental health, the Jersey government has announced plans for new restrictions on the prescribing of CBPMs. Health Minister Tom Binet said he would bring forward new legislation in 2027, requiring doctors who prescribe unlicensed medicinal cannabis to adhere to more stringent practices.

This includes requiring the review of a patient’s medical records before prescribing; requirements to repeatedly meet face-to-face with patients during treatment or before amending the prescribed dose; and required recording of adverse reactions. Doctors will also not be able to prescribe medicinal cannabis unless they have an on-island GMC-responsible officer. 

🇪🇸 Spain’s medical cannabis framework finally reaches patients 

Cannabis-based medicines will finally begin reaching patients in Spain this month after a four-year delay. Proposals for the regulation and distribution of medical cannabis were approved in June 2022, and it was reported that they could be rolled out by the end of that year. Over a year after the Royal Decree came into force in 2025, the first (and only) two preparations will be delivered to around 50 public and private hospitals this week, with a broader national rollout expected by the end of October 2026.

The Medical Cannabis Clinicians Society will hold its first dedicated clinical conference since 2019 on Wednesday 10 March 2027 at King’s House, Manchester, with virtual attendance also available.

No Easy Answers: Cannabis Medicine in the Real World is developed and led by clinicians, bringing together emerging science, practical learning and candid discussion of the decisions shaping patient care. Main-stage sessions, breakouts and panel discussions will explore personalised prescribing, higher-THC treatment, psychiatric risk, shared care and more.

Attendance is open to clinicians and healthcare professionals eligible for MCCS membership, including those new to medical cannabis. Ticket prices have been deliberately kept accessible: £75 for MCCS members, £95 for non-members and £55 for virtual attendance.

View the programme and book your place on our conference page >>

The Medical Cannabis Clinicians Society (MCCS) is calling for urgent action to protect UK patients who rely on Bedrolite following the insolvency of Dutch medical cannabis producer Bedrocan.

Bedrocan Nederland B.V. and Bedrocan International B.V. were declared bankrupt in the Netherlands in October, following the end of the company’s longstanding supply arrangement with the Dutch Office of Medicinal Cannabis (OMC) and delays to planned changes to the Dutch regulatory framework.

The situation is of particular concern for a small number of children in the UK with severe, treatment-resistant epilepsy who are prescribed Bedrolite and for whom maintaining a consistent medicine is clinically extremely important.

There are currently understood to be seven UK prescriptions affected. The issue was raised in the House of Commons on 15 October, where MPs heard that one affected family’s current supply is expected to run out in December.

For these patients, this is not simply a question of changing brand or substituting one cannabis medicine for another. Children with complex, drug-resistant epilepsy may have reached stability only after years of unsuccessful treatment and careful clinical management. Indeed, for children with epilepsy it is highly likely an alternative product will not have the same effect and place the child at risk of seizures, status epilepticus and a 10% chance of death.

MCCS calls on the Government to act

MCCS has written urgently to the Secretary of State for Health and Social Care, the Rt Hon Yvette Cooper MP, asking the UK Government to intervene.

We have asked the Government to work directly with the Dutch authorities to help secure continued access to Bedrolite for affected UK patients, including exploring the release of existing OMC-held stocks and establishing an emergency supply arrangement while a longer-term solution is found.

The Dutch authorities have indicated that existing stocks should be sufficient to continue supplying patients within the Netherlands until at least mid-2027. However, the immediate concern is that these stocks are intended for domestic Dutch supply while established international supply arrangements are disrupted.

Given the very small number of UK patients involved, MCCS believes that every possible avenue should now be explored to protect continuity of treatment.

Raising the issue in Parliament

MCCS has also helped raise the issue directly in Parliament through our role as co-secretariat of the All-Party Parliamentary Group on Medical Cannabis under Prescription. The Society’s wider work with the APPG is focused on raising awareness of barriers to access and finding practical, evidence-based solutions.

A written parliamentary question asks the House whether the Government will take diplomatic and regulatory steps with the Dutch Ministry of Health and the MHRA to secure the emergency export release of existing Bedrolite stocks following Bedrocan’s insolvency.

The question also asks the Government what assessment it has made of the clinical risks to paediatric patients facing an immediate supply shortage, including the risks of status epilepticus and sudden unexpected death in epilepsy.

At the time of writing, a substantive Government response to these questions is awaited.

Medcan Family Foundation launches humanitarian appeal

The Medcan Family Foundation, which supports families of children living with severe treatment-resistant epilepsy, has also issued an urgent humanitarian appeal to the Dutch Ministry of Health and the OMC.

Medcan is requesting urgent discussions with the Dutch authorities and has asked them to consider a targeted, time-limited humanitarian release of existing Bedrolite stocks for affected UK children while sustainable supply routes are restored.

Its appeal calls for an urgent review of available stocks, a lawful export mechanism and coordinated action between the Dutch and UK authorities, while ensuring that the needs of Dutch patients are also protected. With only a small number of UK patients affected, there is an opportunity for governments, regulators, clinicians, suppliers and patient organisations to work together quickly to prevent an avoidable interruption in treatment.

Continuity of care must come first

Medical cannabis has been legally available on prescription in the UK since November 2018, but NHS access remains extremely limited. MCCS has consistently argued that patients who benefit from cannabis-based medicines should be able to access them through appropriate, sustainable healthcare pathways.

The present situation demonstrates why continuity of supply is an important part of that discussion.

Whatever the commercial or regulatory circumstances surrounding Bedrocan’s insolvency, patients who have been established on a medicine and are benefiting from treatment should not become collateral damage.

MCCS will continue working with parliamentarians, clinicians, patient organisations and other stakeholders to press for an urgent solution. We are asking the UK Government and Dutch authorities to work together now to protect these patients and ensure that no child experiences an avoidable interruption to an established and clinically important treatment.

The Medical Cannabis Clinicians Society is pleased to welcome Primus Indemnity as a Recognised Partner, providing our members, prescribers and medical cannabis clinics with greater choice and access to specialist indemnity cover tailored to the unique requirements of the medical cannabis sector.

Medical cannabis is a developing area of clinical practice, and standard indemnity products do not always reflect the way clinicians and clinics work. Primus takes the time to understand each applicant’s practice and provides access to cover designed specifically for prescribing medical cannabis.

The policy offers a £1 million indemnity limit and access to a 24-hour medico-legal helpline provided by an experienced international clinical negligence law firm. It can accommodate clinicians based around the world who prescribe in accordance with the policy terms.

Cover can also include:

Primus also places a strong emphasis on personal service. Its team is available to explain the cover in straightforward terms, answer questions and help clinicians review their indemnity as their practice develops.

As a Recognised Partner, Primus will work with MCCS to support our professional community and build a better understanding of the indemnity and medical cannabis insurance needs of those working in the sector. The partnership will also give members opportunities to learn more about managing medico-legal risk and choosing suitable cover as their practice develops.

Primus joins our network of trusted organisations that share our commitment to high standards, informed clinical practice and better support for the sector.

Find out more

To learn more about Primus cover, discuss your circumstances or request a quotation, contact [email protected], call 07891 447171 or visit primusindemnity.co.uk.

Download more information about Primus Indemnity’s medical cannabis insurance.

Cover is subject to eligibility, underwriting, policy terms, conditions and exclusions.

Each month, we bring together the key news stories shaping the medical cannabis landscape in the UK and beyond.

This month’s headlines highlight the evolving place of cannabis-based medicines in healthcare, research and public policy. Key developments include a pioneering NHS inpatient medical cannabis procedure, the impact of prescribed cannabis on policing in Jersey, major changes to reimbursement in Germany, further progress towards legalisation in France, and the launch of an NIHR-funded clinical trial investigating a potential treatment for chemotherapy-induced peripheral neuropathy.

ACMD medical cannabis review pushed to end of 2026

The highly anticipated Advisory Council on the Misuse of Drugs (ACMD) review into the UK’s medical cannabis framework has received a new target publication date. In an update to Minister of State Sarah Jones on September 21, 2026, ACMD Chair Professor David Wood said the working group is ‘concluding its report’, and expects publication ‘by the end of the year’. , The report was initially expected this summer, after submissions closed on October 17, 2025.

Medical cannabis prescribing under parliamentary scrutiny

Medical cannabis was raised in parliament on two occasions this month, with the government asked specifically about the effectiveness of regulation in protecting patients with severe mental-health conditions, as well as answering questions about whether current prescribing volumes are consistent with patient safety and about enforcement of restrictions on social media advertising. Its response pointed to CQC regulation of private clinics and the ongoing ACMD review, and reiterated that private clinics can advertise services or consultations but not medicinal products. 

CQC publishes new guidance on CBPMs

The Care Quality Commission also published an important update on cannabis-based products for medicinal use (CBPMs), clarifying what the regulator expects from prescribers and providers, particularly around treatment initiation, multidisciplinary review, specialist oversight, shared care and communication with other healthcare professionals. The MCCS was pleased to see that our own best practice prescribing guidelines are referenced in the latest controlled drugs report. Read more on this here. 

Jersey mental health lead warns of “significant increase” in psychosis cases 

A consultation examining medical cannabis prescribing is also underway in Jersey. There has been a “significant increase” in people being taken to hospital for psychosis and mental illness after taking prescribed cannabis, Andy Weir, Jersey’s mental health lead, told The Sunday Times.  Under proposed controls that could be rolled out early next year, clinics will be required to consult in person with patients every 90 days, review medical records before issuing a prescription and report adverse drug reactions, among other measures.

Denmark medical cannabis pilot reports no new concerns as patients rise 

Meanwhile, Denmark’s medicines regulator found no new safety concerns linked to medical cannabis in 2025 despite the number of patients receiving prescriptions rising by more than half. The Danish Medicines Agency received three reports covering four suspected side effects during the year, according to its latest annual safety report. Two reports involved suspected serious side effects, and one involved a non-serious reaction. All three were submitted by doctors.

The Care Quality Commission has published an important update on cannabis-based products for medicinal use (CBPMs).

The update clarifies what the CQC expects from medical cannabis prescribers and providers, particularly around treatment initiation, multidisciplinary review, specialist oversight, shared care and communication with other healthcare professionals.

It also confirms that the CQC has begun an engagement programme with CBPM providers to understand how services operate, manage risk and identify good practice.

What is the latest CQC medical cannabis guidance?

The CQC’s update references the growth in private prescribing of unlicensed CBPMs, reporting that 833,525 items were prescribed between April 2024 and March 2025, an increase of 134% on the previous year. As prescribing increases, it is clear the CQC requires services to demonstrate that decisions are clinically justified, properly reviewed and supported by effective clinical governance.

The Medical Cannabis Clinicians Society is pleased to be specifically referenced in the latest CQC controlled drugs update. The CQC notes that the Society has strengthened its guidance for CBPM prescribers. Although it does not formally endorse external guidance, it describes principles within the MCCS Good Practice Guide as helpful and says they align with its expectations.

The CQC highlights two MCCS principles:

What does the CQC expect from CBPM providers?

The CQC states that providers must have a process to scrutinise and ratify every decision to initiate a CBPM. This process should confirm that the decision is patient-centred, clinically appropriate and supported by a clearly established unmet clinical need.

Independent providers may manage this through a multidisciplinary team, clinical governance board or another proportionate governance process. Providers must maintain an effective audit trail showing who reviewed the case, what information was considered and how the decision was reached.

CBPM multidisciplinary team requirements

Services must ensure that their processes allow at least two doctors on the GMC Specialist Register to participate in scrutinising and ratifying prescribing decisions.

The prescribing specialist must practise in the clinical specialty relevant to the condition being treated. Other specialists taking part must have sufficient knowledge of that clinical area to provide meaningful scrutiny.

Reviews may take place in person or through an appropriate asynchronous process, but they must involve genuine clinical review rather than administrative sign-off.

Specialist oversight and shared care

The CQC has seen examples of care being delegated entirely to non-specialists, with little continuing involvement from the initiating specialist. Services must be able to demonstrate that the specialist retains oversight and remains practically involved in the patient’s care. The level of involvement should reflect the patient’s condition, response to treatment and individual needs.

Where supplementary prescribers are involved, treatment must follow a thorough, patient-specific Clinical Management Plan. This should set out the agreed treatment, monitoring arrangements, permitted adjustments and when the specialist must be consulted again.

Communication and registration

Medical cannabis prescribers need complete and accurate clinical information before making a prescribing decision. Relevant healthcare professionals should also be informed about treatment. Depending on the patient, this may include their GP, specialists, mental health services, other independent providers and the dispensing pharmacy.

Providers already registered with the CQC for the regulated activity of Treatment of disease, disorder or injury must update their statement of purpose if they begin offering CBPM treatment. The CQC must be notified in writing within 28 days of the change.

What is the CQC CBPM engagement programme?

The CQC has begun an engagement programme with CBPM providers. The programme will help the regulator understand the services being provided, how risks are managed and where good practice is taking place. Information gathered will also inform its ongoing monitoring activity.

The CQC is requesting information on:

Supporting medical cannabis prescribers

Medical cannabis is a developing area of clinical practice. Prescribers must navigate unlicensed medicines, controlled drug regulations, changing regulatory expectations and a growing evidence base. Specialist consultants, GPs, pharmacists, nurses, allied health professionals, medical students and other clinicians can get much-needed support from the Society.

MCCS membership provides access to:

Whether you already prescribe medical cannabis, are preparing to prescribe or support patients in another clinical role, the Society can help you practise safely and with confidence. Join the Medical Cannabis Clinicians Society and become part of the independent clinical community working to improve CBPM care.

Is your clinic committed to good practice?

Clinics can demonstrate their support for high standards by joining the MCCS Clinics Committed to Good Practice initiative.

Participating clinics complete an annual voluntary declaration confirming their support for specialist-led prescribing, appropriate MDT oversight, structured monitoring, clear documentation, transparency and continuing professional development.

The initiative is based on voluntary self-declaration and annual renewal. It is not an accreditation or inspection scheme.

If your clinic has not yet signed up, speak to your clinical and governance teams about taking part.

Find out more and complete the declaration.

Each month, we bring together the key news stories shaping the medical cannabis landscape in the UK and beyond.

This month’s headlines highlight the evolving place of cannabis-based medicines in healthcare, research and public policy. Key developments include a pioneering NHS inpatient medical cannabis procedure, the impact of prescribed cannabis on policing in Jersey, major changes to reimbursement in Germany, further progress towards legalisation in France, and the launch of an NIHR-funded clinical trial investigating a potential treatment for chemotherapy-induced peripheral neuropathy.

NHS trust approves inpatient medical cannabis policy

Devon Partnership NHS Trust (DPT) NHS trust has approved a standard procedure for patients to continue taking their prescribed cannabis-based medications while in hospital.The policy, which aims to give medical cannabis patients a clear, safe pathway when admitted, was approved in May. 

The mental health and learning disability trust is among the first in England to establish procedures for verifying prescriptions, storing medicines, and administering treatment safely where appropriate, since medical cannabis was legalised in 2018.

???? Read more 

Medicinal cannabis making policing ‘more complex’ in Jersey

Medicinal cannabis use has made it more difficult for police officers in Jersey to distinguish between legal and illegal drug use, despite fewer people being charged with drug offences, senior officers have said.

States of Jersey Police said more islanders accessing prescribed medicinal cannabis had reduced demand for illegal imports of the drug. The force’s first Crime and Policing Statistics report showed there were 55 fewer arrests between 2022 and 2025.

???? Read more 

Germany bans medical cannabis flower from reimbursement 

Germany has voted to ban medical cannabis flower from its statutory health insurance scheme, in a broad savings package, which passed through the Bundestag on 10 July. This will mean medical cannabis flower is no longer reimbursed, while patients seeking cover for extracts must first undergo a mandatory six-month course of an approved cannabis-based finished medicine.

???? Read more 

France’s medical cannabis framework edges closer to legalisation 

France’s incoming legal framework for the prescription of cannabis-based medicines has edged closer to clearing the final hurdle. According to Newsweed the Minister Delegate for Relations with Parliament confirmed the text has received approval from the Ministry of Economy, Finance and Industrial and Digital Sovereignty, and was submitted to the Conseil d’État for review, the final step before becoming law.  

???? Read more 

Ananda Pharma doses first patient in NIHR-backed CIPN trials

Ananda Pharma has dosed the first patient in the ACTiON trial, a Phase 2 NIHR-funded study evaluating MRX1, the company’s proprietary CBD-based oral solution, as a treatment for chemotherapy-induced peripheral neuropathy (CIPN), a debilitating nerve-damage condition caused by chemotherapy for which no effective therapies currently exist.

???? Read more 

Join the Society

If you want to stay informed, supported, and part of the independent clinical voice shaping medical cannabis in the UK, join the Medical Cannabis Clinicians Society.

Membership gives you access to expert guidance, CPD-accredited education, peer support, and regular sector updates like this one. Join the Society to be part of the conversation and help drive better, evidence-based care.

We are delighted to share the second-prize essay from our inaugural Medical Cannabis Student Essay Competition, written by Taranjot Bhoot, a second-year Medical Physiology undergraduate at the University of Leicester.

In Medical Cannabis for Endometriosis: Should It Have a Place in Clinical Practice?, Taranjot examines the significant treatment gap experienced by many people with endometriosis and considers whether cannabis-based medicines could offer another option for managing complex, persistent pain.

The essay explores the role of the endocannabinoid system in reproductive physiology and evaluates emerging evidence for medical cannabis. Taranjot carefully balances its potential benefits against important questions surrounding safety, evidence quality, cost, stigma and equitable access.

Rather than suggesting that the evidence is settled, she argues for a broader evidence framework combining emerging clinical trials, including ENDOCAN-1, with high-quality real-world registry data to inform safe and evidence-based clinical practice.

???? Download and read Taranjot Bhoot’s essay

Congratulations to Taranjot on an insightful and academically rigorous submission. Her work reflects the curiosity, critical thinking and commitment to evidence-based care that the Society hopes to encourage among the next generation of clinicians and medical researchers.

About the author

Taranjot’s interest in the endocannabinoid system developed while studying reproduction, inspiring her to investigate how cannabinoid receptor modulation might be used to manage reproductive disorders. She aspires to become a clinician-scientist, translating emerging medical research into safe, evidence-based patient care.

The competition forms part of the Society’s wider commitment to supporting medical students and the next generation of clinicians.